Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTL NASDAQ:INBX NASDAQ:ONCY NASDAQ:PRTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.46+0.7%$2.14$1.11▼$5.00$388.57M1.873.41 million shs8.77 million shsINBXInhibrx Biosciences$28.18+1.7%$22.82$10.81▼$28.73$408.19M0.33103,413 shs151,227 shsONCYOncolytics Biotech$1.06-1.9%$1.04$0.33▼$1.53$106.38M1.19712,671 shs269,926 shsPRTCPureTech Health$16.34+3.0%$18.11$13.30▼$24.99$391.71M1.115,289 shs8,633 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%-2.67%-37.87%-37.61%-64.39%INBXInhibrx Biosciences0.00%-0.07%+32.05%+102.44%+75.69%ONCYOncolytics Biotech0.00%+1.92%+15.83%+194.44%+4.95%PRTCPureTech Health0.00%-4.31%-8.23%-13.46%-24.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.46+0.7%$2.14$1.11▼$5.00$388.57M1.873.41 million shs8.77 million shsINBXInhibrx Biosciences$28.18+1.7%$22.82$10.81▼$28.73$408.19M0.33103,413 shs151,227 shsONCYOncolytics Biotech$1.06-1.9%$1.04$0.33▼$1.53$106.38M1.19712,671 shs269,926 shsPRTCPureTech Health$16.34+3.0%$18.11$13.30▼$24.99$391.71M1.115,289 shs8,633 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%-2.67%-37.87%-37.61%-64.39%INBXInhibrx Biosciences0.00%-0.07%+32.05%+102.44%+75.69%ONCYOncolytics Biotech0.00%+1.92%+15.83%+194.44%+4.95%PRTCPureTech Health0.00%-4.31%-8.23%-13.46%-24.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.12524.66% UpsideINBXInhibrx Biosciences 2.00HoldN/AN/AONCYOncolytics Biotech 2.80Moderate Buy$5.00371.70% UpsidePRTCPureTech Health 3.50Strong Buy$45.00175.48% UpsideCurrent Analyst Ratings BreakdownLatest ONCY, PRTC, INBX, and AUTL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/22/2025INBXInhibrx BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/13/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$6.00 ➝ $5.008/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.007/21/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/12/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$29.93M12.98N/AN/A$1.61 per share0.91INBXInhibrx Biosciences$1.40M291.56$117.42 per share0.24$9.23 per share3.05ONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/APRTCPureTech Health$4.83M81.61$2.40 per share6.81$17.04 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$220.66M-$0.84N/AN/AN/AN/A-56.18%-29.61%11/11/2025 (Estimated)INBXInhibrx Biosciences$1.69B-$10.58N/AN/AN/AN/A-137.83%-76.31%11/13/2025 (Estimated)ONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)PRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ALatest ONCY, PRTC, INBX, and AUTL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025INBXInhibrx Biosciences-$2.92-$1.85+$1.07-$1.85N/A$1.30 million8/12/2025Q2 2025AUTLAutolus Therapeutics-$0.24-$0.18+$0.06-$0.18$12.92 million$13.50 million8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A8.438.07INBXInhibrx Biosciences1.454.984.98ONCYOncolytics BiotechN/A2.882.88PRTCPureTech HealthN/A8.499.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%INBXInhibrx Biosciences82.46%ONCYOncolytics Biotech6.82%PRTCPureTech Health0.04%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%INBXInhibrx Biosciences17.09%ONCYOncolytics Biotech0.10%PRTCPureTech Health5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.74 millionOptionableINBXInhibrx Biosciences16614.49 million12.01 millionOptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionablePRTCPureTech Health10024.13 million22.85 millionNot OptionableONCY, PRTC, INBX, and AUTL HeadlinesRecent News About These CompaniesPureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call TranscriptAugust 29, 2025 | insidermonkey.comPureTech Health plc (PRTC) Q2 2025 Earnings Conference Call TranscriptAugust 28, 2025 | seekingalpha.comPureTech Health plc – Half-Year ReportAugust 28, 2025 | businesswire.comPureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Down 39.6% in JulyAugust 21, 2025 | marketbeat.comPureTech Health: Notice of Half-Yearly ResultsAugust 18, 2025 | businesswire.comPureTech Health (NASDAQ:PRTC) Trading Up 1.4% - Still a Buy?August 15, 2025 | marketbeat.comPureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary EndpointAugust 13, 2025 | businesswire.comPureTech Health plc: PureTech Announces Board ChangeJuly 31, 2025 | finanznachrichten.dePureTech CEO Bharatt Chowrira steps downJuly 16, 2025 | thepharmaletter.comTPureTech Health CEO Bharatt Chowrira ResignsJuly 16, 2025 | marketwatch.comPureTech Announces Leadership TransitionJuly 16, 2025 | businesswire.comPureTech Health announces board chair Raju Kucherlapati steps downJuly 10, 2025 | investing.comPureTech Health plc (PRTC) Income Statement - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comPureTech Announces Board ChangeJuly 8, 2025 | businesswire.comWhy This Biotech Stock Just Doubled In A Single DayJune 26, 2025 | benzinga.comPureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF TrialMay 22, 2025 | businesswire.comPureTech’s deupirfenidone shows strong and durable efficacyMay 21, 2025 | thepharmaletter.comTPureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)May 9, 2025 | businesswire.comPureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International ConferenceMay 1, 2025 | finance.yahoo.comPureTech to Present Results from Phase 2b ELEVATE…May 1, 2025 | pharmiweb.comPPureTech Health plc (PRTC) Q4 2024 Earnings Call TranscriptApril 30, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCY, PRTC, INBX, and AUTL Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.46 +0.01 (+0.69%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.49 +0.03 (+2.05%) As of 09/5/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Inhibrx Biosciences NASDAQ:INBX$28.18 +0.46 (+1.66%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$28.16 -0.02 (-0.07%) As of 09/5/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Oncolytics Biotech NASDAQ:ONCY$1.06 -0.02 (-1.85%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.08 +0.02 (+2.36%) As of 09/5/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.PureTech Health NASDAQ:PRTC$16.34 +0.48 (+2.99%) Closing price 09/5/2025 03:51 PM EasternExtended Trading$16.13 -0.21 (-1.25%) As of 09/5/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
